Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma

The clinical management of metastatic melanoma has been changed by BRAF (BRAFi) and MEK inhibitors (MEKi), which represent a standard treatment for <i>BRAF</i>-mutant melanoma. In oligoprogressive melanoma patients with <i>BRAF</i> mutations, target therapy can be combined wi...

Full description

Bibliographic Details
Main Authors: Ernesto Rossi, Giovanni Schinzari, Francesco Cellini, Mario Balducci, Mariangela Pasqualoni, Brigida Anna Maiorano, Bruno Fionda, Silvia Longo, Francesco Deodato, Alessandro Di Stefani, Ketty Peris, Maria Antonietta Gambacorta, Giampaolo Tortora
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Biomedicines
Subjects:
metastatic melanoma
BRAF inhibitors
MEK inhibitors
radiotherapy
case series
BRAF
Online Access:https://www.mdpi.com/2227-9059/11/2/394

Internet

https://www.mdpi.com/2227-9059/11/2/394

Similar Items